---
layout: home
title: Dr. Narender Kumar
---

<meta name="description" content="Official website of Dr. Narender Kumar. Research, publications, academic profile and professional work.">
<meta name="keywords" content="Dr Narender Kumar, Oncology, Medical Oncology, Molecular Oncology, Cancer, Doctor, Internal Medicines, Medicine, Clinical, Clincal Research,  Researcher, Physician, Scientist, MBBS, MRCPUK, MRCP (UK), PhD, Harvard, Sardar Patel Medical College, Marie Curie ">
<meta name="author" content="Dr Narender Kumar">
<meta name="robots" content="index, follow">

<div style="display: flex; align-items: center; gap: 40px; flex-wrap: wrap; margin-top: 30px;">

  <img src="/assets/images/nk_photo_portrait.jpg" alt="Dr. Narender Kumar" 
       style="width: 220px; border-radius: 8px; box-shadow: 0 6px 18px rgba(0,0,0,0.15);">

  <div>
    <h1 style="margin-bottom: 5px;">Dr. Narender Kumar</h1>
    <p style="font-size: 18px; margin-top: 0;">
      <strong>MBBS, MRCP (UK), PhD</strong><br>
      Physician • Researcher • Harvard Alumnus • Marie Skłodowska-Curie Fellow<br>
      <strong>Medical Oncology | Internal Medicine | Molecular Oncology | Clinical Research</strong>
    </p>
  </div>

</div>

<hr style="margin: 40px 0;">


---

## About

Dr. Narender Kumar is a dedicated physician and medical researcher with a strong academic foundation and global clinical experience spanning internal medicine, oncology, and molecular life sciences. He earned his MBBS from Sardar Patel Medical College, Bikaner (Rajasthan University of Health Sciences) and later completed a PhD in Molecular Life Sciences as a Marie Skłodowska-Curie Fellow at the Institute of Experimental Endocrinology and Oncology (CNR), Naples, Italy, in collaboration with the University of Campania “Luigi Vanvitelli.” He also holds a Postgraduate Fellowship in Clinical Trials from Harvard Medical School and is a Member of the Royal College of Physicians of the United Kingdom (MRCP, UK).

---

## Research focus

Dr. Kumar’s research focuses on molecular oncology, immuno-oncology, and personalized cancer therapy. His PhD work explored PD-1/PD-L1 signalling in thyroid cancer, contributing to the understanding of intrinsic immune checkpoint mechanisms in tumor progression. He has authored over 24 peer-reviewed publications and presented extensively at international forums such as ESMO, AACR, and IASGO, accumulating more than 400 citations with an h-index of 11.

---

## Professioanl experience

Professionally, Dr. Kumar has served in diverse medical and research roles, including positions at Delhi State Cancer Institute, AIIMS Rishikesh, Government Doon Medical College, and the National Research Council (CNR), Italy. Currently, he serves in department of Medical Oncology at Homi Bhabha Cancer Hospital & Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, India. His previous leadership as In-Charge Medical Officer at the Community Health Centre, Pauri Garhwal, reflects his strong commitment to public health and clinical excellence in rural healthcare delivery.

---

## Fellowships and awards
Dr. Kumar is a recipient of numerous international awards and fellowships, including the Marie Skłodowska-Curie Fellowship (EU Horizon 2020), Harvard Medical School Scholarship, and multiple ESMO International Cancer Foundation (ICF) scholarships. He is an active member of global professional societies, including ESMO, ASCO, AACR, ASTRO, and the Marie Curie Alumni Association.

---

## Leadership and management 

Beyond his clinical and research pursuits, Dr. Kumar has demonstrated leadership and teaching excellence, having mentored healthcare professionals and contributed to institutional academic activities. His career exemplifies the integration of patient care, translational research, and international collaboration toward advancing evidence-based medicine.

---

## Contact

[Email](narender@alumni.harvard.edu)    
[Twitter: X](https://x.com/NKSantoriya)    
[ORCID](https://orcid.org/0000-0002-2427-647X)  
[Google Scholar](https://scholar.google.com/citations?user=UC8BFsUAAAAJ&hl=en)    
